首页> Clinical breast cancer> The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study.

The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study.

导出原文传递

翻译打印收藏纠错

第一作者： Xi,Chen

第一单位： Xi'an Jiaotong University, Shaanxi Province, China.

作者： Xi,Chen ^[1] ; Xinyu,Wei ^[1] ; Peizhuo,Yao ^[1] ; Yanbin,Liu ^[1] ; Haitao,Guan ^[2] ; Huafeng,Kang ^[2] ; Di,Liu ^[2] ; Yan,Diao ^[2] ; Xiaobin,Ma ^[2] ; Weili,Min ^[2] ; Changyou,Shan ^[2] ; Yang,Zhao ^[2] ; Fang,Zhao ^[2] ; Yuanyuan,Chen ^[3] ; Dong,Xiao ^[4] ; Qing,She ^[3] ; Youhuai,Liu ^[3] ; Yinbin,Zhang ^[2] ; Shuqun,Zhang ^[5]

作者单位： Xi'an Jiaotong University, Shaanxi Province, China. ^[1] The Second Affiliated Hospital of Xi'an Jiaotong University, Shaanxi Province, China. ^[2] Baoji Central Hospital of Shaanxi Province, Shaanxi Province, China. ^[3] 3201 Hospital of Hanzhong City, Shaanxi Province, China. ^[4] The Second Affiliated Hospital of Xi'an Jiaotong University, Shaanxi Province, China. Electronic address: zhangshuqun1971@aliyun.com. ^[5]

关键词 Anti-angiogenesis Clinical research Long term observation Neoadjuvant therapy